Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC, 10731-10732 [2025-03061]
Download as PDF
<![CDATA[
10731
Federal Register / Vol. 90, No. 37 / Wednesday, February 26, 2025 / Notices
Sharp Clinical Services, LLC
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before March 28, 2025. Such
persons may also file a written request
for a hearing on the application on or
before March 28, 2025.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
SUMMARY:
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on January 7, 2025, Sharp
Clinical Services, LLC, 2400 Baglyos
Circle, Bethlehem, Pennsylvania 18020–
8024, applied to be registered as an
importer of the following basic class(es)
of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
Gamma Hydroxybutyric Acid ...........................................................................................................................................
3,4-Methylenedioxymethamphetamine ............................................................................................................................
5-Methoxy-N-N-dimethyltryptamine .................................................................................................................................
Psilocybin .........................................................................................................................................................................
The company plans to import the
listed controlled substances for
distribution and clinical trials. No other
activities for these drug codes are
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2025–03060 Filed 2–25–25; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1503]
Importer of Controlled Substances
Application: Catalent Pharma
Solutions, LLC
Drug Enforcement
Administration, Justice.
khammond on DSK9W7S144PROD with NOTICES
AGENCY:
ACTION:
Notice of application.
Catalent Pharma Solutions,
LLC has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before March 28, 2025. Such
persons may also file a written request
for a hearing on the application on or
before March 28, 2025.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
SUMMARY:
In
accordance with 21 CFR 1301.34(a), this
is notice that on November 19, 2024,
Catalent Pharma Solutions, LLC, 3031
Red Lion Road, Philadelphia,
Pennsylvania 19114–1123, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Drug code
Ibogaine ...........................................................................................................................................................................
VerDate Sep<11>2014
18:26 Feb 25, 2025
Jkt 265001
research, and analytical activities. No
other activity for this drug code is
authorized for this registration.
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
I
I
I
I
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
Controlled substance
The company plans to import the
listed controlled substance as finished
dosage unit products for clinical trials,
2010
7405
7431
7437
Schedule
7260
Schedule
I
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
E:\FR\FM\26FEN1.SGM
26FEN1
10732
Federal Register / Vol. 90, No. 37 / Wednesday, February 26, 2025 / Notices
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2025–03061 Filed 2–25–25; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1501]
Importer of Controlled Substances
Application: S&B Pharma LLC DBA
Norac Pharma
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
S&B Pharma LLC DBA Norac
Pharma has applied to be registered as
SUMMARY:
an importer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before March 28, 2025. Such
persons may also file a written request
for a hearing on the application on or
before March 28, 2025.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on December 9, 2024, S&B
Pharma LLC DBA Norac Pharma, 405
South Motor Avenue, Azusa, California
91702, applied to be registered as an
importer of the following basic class(es)
of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
4-Anilino-N-phenethyl-4-piperidine (ANPP) .....................................................................................................................
Tapentadol .......................................................................................................................................................................
The company plans to import
intermediate forms of Tapentadol (9780)
for further manufacturing prior to
distribution to its customers. The
company plans to import ANPP (8333)
to bulk manufacture other controlled
substances for distribution to its
customers. No other activities for these
drug codes are authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
khammond on DSK9W7S144PROD with NOTICES
BILLING CODE 7555–01–P
[Docket Nos. MC2025–1189 and K2025–
1189; MC2025–1190 and K2025–1190;
MC2025–1191 and K2025–1191]
BILLING CODE P
New Postal Products
NATIONAL SCIENCE FOUNDATION
Astronomy and Astrophysics Advisory
Committee; Cancellation of Meeting
National Science Foundation.
Notice; Cancellation of meeting
AGENCY:
date.
18:26 Feb 25, 2025
[FR Doc. 2025–03097 Filed 2–25–25; 8:45 am]
POSTAL REGULATORY COMMISSION
[FR Doc. 2025–03062 Filed 2–25–25; 8:45 am]
VerDate Sep<11>2014
Dated: February 21, 2025.
Crystal Robinson,
Committee Management Officer, National
Science Foundation.
II
II
notice informs the public of the filing,
invites public comment, and takes other
administrative steps.
DATES: Comments are due: February 28,
2025.
ADDRESSES: Submit comments
electronically via the Commission’s
Filing Online system at https://
www.prc.gov. Those who cannot submit
comments electronically should contact
the person identified in the FOR FURTHER
INFORMATION CONTACT section by
telephone for advice on filing
alternatives.
FOR FURTHER INFORMATION CONTACT:
David A. Trissell, General Counsel, at
202–789–6820.
SUPPLEMENTARY INFORMATION:
Table of Contents
Matthew Strait,
Deputy Assistant Administrator.
ACTION:
The National Science Foundation
published a notice in the Federal
Register January 28, 2025, in FR Doc.
2025–01779 at 90 FR 8306, concerning
a meeting of the Astronomy and
Astrophysics Advisory Committee. The
meeting scheduled for Tuesday,
February 25, 2025, at 10 a.m. (ET) is
cancelled.
FOR FURTHER INFORMATION CONTACT:
Please contact Crystal Robinson
crrobins@nsf.gov or 703–292–8687.
8333
9780
Schedule
Jkt 265001
Postal Regulatory Commission.
Notice.
AGENCY:
ACTION:
The Commission is noticing a
recent Postal Service filing for the
Commission’s consideration concerning
a negotiated service agreement. This
SUMMARY:
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
I. Introduction
II. Public Proceeding(s)
III. Summary Proceeding(s)
I. Introduction
Pursuant to 39 CFR 3041.405, the
Commission gives notice that the Postal
Service filed request(s) for the
Commission to consider matters related
to Competitive negotiated service
agreement(s). The request(s) may
propose the addition of a negotiated
service agreement from the Competitive
product list or the modification of an
E:\FR\FM\26FEN1.SGM
26FEN1
]]>Agencies
[Federal Register Volume 90, Number 37 (Wednesday, February 26, 2025)]
[Notices]
[Pages 10731-10732]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-03061]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1503]
Importer of Controlled Substances Application: Catalent Pharma
Solutions, LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Catalent Pharma Solutions, LLC has applied to be registered as
an importer of basic class(es) of controlled substance(s). Refer to
Supplementary Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants, therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
March 28, 2025. Such persons may also file a written request for a
hearing on the application on or before March 28, 2025.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on November 19, 2024, Catalent Pharma Solutions, LLC,
3031 Red Lion Road, Philadelphia, Pennsylvania 19114-1123, applied to
be registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Ibogaine........................... 7260 I
------------------------------------------------------------------------
The company plans to import the listed controlled substance as
finished dosage unit products for clinical trials, research, and
analytical activities. No other activity for this drug code is
authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what
[[Page 10732]]
is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend
to the import of Food and Drug Administration-approved or non-approved
finished dosage forms for commercial sale.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2025-03061 Filed 2-25-25; 8:45 am]
BILLING CODE P
